Technological breakthrough - 7

 

Fig. 2 Vaccination and SARS-CoV-2 variant timeline. The timeline plot shows the vaccinations periods for each group in relation to the dominant SARS-CoV-2 variant circulating in the UK at the time. Dots with an “×” indicate participants who were infected with COVID-19 prior to reaching Day 56 (Week 8), including one participant who was enrolled in error. Epidemiological data on SARS-CoV-2 variant spread was sourced from (https://ukhsa-dashboard.data.gov.uk/respiratory-viruses/covid-19)

1. Computer-Designed Vaccine Human Trials

• Annotation: In June 2026, researchers successfully initiated the first-ever human clinical trial for a vaccine where the active component was completely engineered using computer simulations. Conducted by the University of Cambridge and DIOSynVax, this milestone moves vaccinology away from traditional biological isolation methods, leveraging predictive AI algorithms to design hyper-targeted antigens against pathogens.
• Reference: Reported globally across medical media outlets:
• https://www.journalofinfection.com/article/S0163-4453(26)00084-8/fulltext#fig0010
• https://www.cam.ac.uk/research/news/new-universal-vaccine-technology-could-protect-us-from-future-virus-outbreaks   

Figure 1Efficient and precise gene editing by ABE after injection in human zygotes.

a, Schematic illustrating genomic location of two target genes, PCSK9 and HBG1/2, and sequences of used sgRNAs. b, Workflow for ABE mRNA or ABE ribonucleoprotein (RNP) delivery into two-pronuclear (2PN) human zygotes and analysis of whole-genome-amplified (WGA) samples from single cells collected from injected embryos. c-e, Sanger sequencing chromatograms showing base editing outcomes at two targeted loci, PCSK9 (c) and HBG1/2 (d, e). Two types of insertions detected at HBG1/2 are depicted (e) with Sanger sequencing chromatograms and nucleotide base sequences according to the analysis using EditR48. f, g, Quantification of editing outcomes based on Sanger sequencing of single cells isolated from ABE mRNA- (f) and RNP-edited (g) human embryos.

2. The Dawn of Base-Edited Genetic Therapeutics

• Annotation: Moving beyond traditional CRISPR "gene cutting," 2026 marked a massive shift toward base editing. Media highlighted cases like baby KJ, the first patient to receive a highly personalized, base-edited gene treatment to cure an inherited condition without damaging surrounding DNA. Simultaneously, researchers published the first instance of using base editing safely on early-stage human embryos to correct hereditary defects. [1, 2]
• Reference: Published extensively in MIT Technology Review's 10 Breakthrough Technologies 2026 and preprint medical archives like bioRxiv:

- https://www.biorxiv.org/content/10.64898/2026.05.30.728989v1.full

- https://www.nature.com/articles/d41586-026-01827-8

- https://www.nytimes.com/2026/06/04/science/embryos-gene-editing-crispr.html

The bacterium Neisseria gonorrhoeae has developed some degree of resistance to all currently available antibiotics.Richard J. Green/Science Source

3. Science's "Breakthrough of the Year": Dual Next-Gen Antibiotics

• Annotation: Published in late December 2025, Phase 3 human trials officially confirmed the success of two entirely new classes of oral antibiotics: Gepotidacin and Zoliflodacin. Developed to combat antibiotic-resistant superbugs (specifically N. gonorrhoeae), these pills target the bacteria's DNA replication mechanisms in a novel way, offering a vital defense against the global threat of antimicrobial resistance. [1]
• Reference: Formally published in The Lancet and crowned as the Breakthrough of the Year by the American Association for the Advancement of Science (Science Magazine, December 2025)

- https://www.science.org/content/article/new-antibiotic-gonorrhea-could-help-beat-back-drug-resistant-infections

- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00628-2/abstract